Company news

Geron Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

December 9, 2024

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

November 26, 2024

Geron to Participate in the Stifel 2024 Healthcare Conference

November 10, 2024

Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

November 10, 2024

Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 6, 2024

Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors

November 6, 2024

Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies

November 4, 2024

Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024

October 14, 2024

Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

September 8, 2024

Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights

August 7, 2024

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

July 25, 2024

Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024

July 22, 2024

Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

July 17, 2024

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

June 5, 2024

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

April 24, 2024

Geron to Participate at Upcoming Investor Conferences in April

April 2, 2024

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

March 18, 2024

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

March 13, 2024

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

February 13, 2024

Geron to Participate in the B. Riley Securities Virtual Oncology Conference

January 11, 2024

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

December 10, 2023

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

December 5, 2023

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

December 3, 2023

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

November 27, 2023

Geron to Participate at Upcoming Investor Conferences in November

November 6, 2023

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

November 1, 2023

Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results

November 1, 2023

Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023

October 25, 2023

Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

September 28, 2023

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer

September 10, 2023

Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting

September 6, 2023

Geron to Participate in the Baird 2023 Global Healthcare Conference

September 4, 2023

Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

August 21, 2023

Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS

August 20, 2023

Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results

August 2, 2023

Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023

July 26, 2023

Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

June 28, 2023

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 21, 2023

Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat

June 19, 2023

Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

June 12, 2023

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

June 11, 2023

Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

June 6, 2023

Geron to Host Virtual Investor Event on June 14, 2023

June 5, 2023

Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients

June 1, 2023

Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

May 24, 2023

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

May 10, 2023

Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights

May 10, 2023

Geron to Announce First Quarter 2023 Financial Results on May 11, 2023

May 3, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 32 decks. Every deck is listed under its year.